Latest News

Our group attended EANM 2023 in Vienna, Austria. We had a wonderful time presenting our work and engaging with the nuclear medicine community.

Ayca Løndalen received the prize for Clinical Paper of the Year for her work published in “FDG PET/CT and Dosimetric Studies of [177Lu]Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent Non-Hodgkin Lymphoma—Are We Hitting the Target?” in Molecular Imaging and Biology. The award was presented at the World Molecular Imaging Congress in Prague.

On Thursday, 25.08.2023, Ebba Gløersen Muller defended her PhD thesis titled “[18F]Flutemetamol PET/CT for the Diagnosis of Alzheimer’s Disease – Clinical Value and Reference Levels.” We congratulate Ebba, as well as the supervisory team: Mona-Elisabeth Revheim (main supervisor), Anne Brita Knapskog, and Caroline Stokke.

On Thursday, 02.02.2023, our research group member Ayca Løndalen (MD) defended her PhD thesis titled “FDG PET/CT and Dosimetry Studies After Targeted Therapy with [177Lu]Lu-Lilotomab Satetraxetan.” She was supervised by Caroline Stokke (main supervisor), Mona-Elisabeth Revheim, and Arne Kolstad.

In 2022, the group focused on advancing the understanding of radionuclide therapies and improving dosimetry methods. A total of eight publications were produced, including both original research and a review paper on radionuclides for targeted therapy. Notable studies included dosimetric studies of 177Lu-lilotomab satetraxetan in non-Hodgkin lymphoma and contributions to the EANM dosimetry committee’s recommendations for 177Lu-labelled ligands.

Presentations were delivered at key international and national conferences. Highlights include invited talks at the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI), covering topics such as first-in-human dosimetry, the biodistribution of radium-224, and imaging advancements with Lead-212. Several national talks also focused on dosimetry for alpha-particles and PRRT.

The year also involved continued mentoring of graduate students, with one doctoral student and one master’s student successfully completing their theses under the group’s supervision. The group participated in abstract committees for both the EANM 2023 and NACP 2023 conferences, as well as chaired sessions at EANM 2022.

Overall, 2022 was a year of productive research dissemination and mentorship, with significant contributions to both the scientific community and education.

Caroline will lead a work package focusing on targeted alpha therapy, funded by a grant from the South-Eastern Norway Regional Health Authority. We will recruit a PhD student for this project.

Our group leader of Theragnostic Imaging has been appointed vice chair of the Dosimetry Committee within the European Association of Nuclear Medicine (EANM). In this role, she contributes to advancing the field of dosimetry.

On 18.02.2022, Johan Blakkisrud defended his PhD thesis titled “Dosimetry in Patients Treated with [177Lu]Lu-lilotomab Satetraxetan.” He was supervised by Caroline Stokke (main supervisor), Anne Catrine Martinsen, and Arne Kolstad. The work was funded by a grant from the South-Eastern Norway Regional Health Authority.